Eli Lilly announced positive Phase 1 results for AJ1-11095, a novel type II JAK2 inhibitor targeting myelofibrosis patients who failed type I JAK2 inhibitors. The drug demonstrated a strong safety profile, significant spleen size reduction, symptom improvement, and mutation burden decrease in a trial of 23 patients. These findings suggest a new treatment option for patients with limited alternatives. Lilly plans to advance clinical development and explore broader applications in related blood disorders.
At the American Diabetes Association conference, leading drugmakers like Eli Lilly and Novo Nordisk showcased new obesity treatments including advanced GLP-1 pills and shots promising greater weight loss and easier dosing schedules. Eli Lilly's exper...
Eli Lilly's stock has surged over 20% recently, driven mainly by two obesity drugs, Mounjaro and Zepbound, but this growth is risky due to heavy reliance on few products and price pressures. Investors are paying high multiples amid peak hype, which m...
Eli Lilly reported a strong Q1 2026 with revenue up 55.5%, driven by its obesity drug Mounjaro and new oral GLP-1 pill Foundayo, raising its full-year guidance. In contrast, Novo Nordisk saw a 4% adjusted sales decline, job cuts, and challenges inclu...
About 30 million Americans use GLP-1 drugs, which chemically suppress appetite and reduce fast food demand by 27-30%. This structural shift benefits companies like Amazon, which is expanding its pharmacy and delivery services; Eli Lilly, leading with...
Healthcare ETFs provide a blend of defensive stability and growth potential by covering broad healthcare sectors and specialized themes like biotechnology, pharmaceuticals, and weight-loss treatments. Aging populations and rising healthcare demand su...
